Business
CYTOKINETICS INC: Bank National Association), as trustee, as supplemented by the First Supplemental Indenture, dated November 13, 2019, between Cytokinetics and U.S.
Revenue increased 376.6% to $88.0M, while Net income decreased 33.2% to ($785.0M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $88.0MWatch
- Profitability — Net income ($785.0M)Watch
- Cash generation — Free cash flow ($534.8M)Note
- Accounting — Formula distress score · manipulation flag raised · earnings quality greyWatch
- Insiders — 0 buys; 59 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as CYTOKINETICS INC reports it. History and quarterly detail are in the app.
- License And Milestone Revenues$79.4M
- Collaboration Revenues$8.7M
Leadership changes
From CYTOKINETICS INC's own filings, the day they're filed.
- Santo J. Costa · Directors · departureeff. 2024-11-01
- Sandford D. Smith · Directors · departureeff. 2024-05-15
- Sung H. Lee · President · appointmenteff. 2024-05-08
Latest filings
- 8-K · Company announcement2026-08-28
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-05-27
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CYTOKINETICS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.